SCHEMBL3247619

SCHEMBL3247619

COc1cc([N+](=O)[O-])ccc1NS(C)(=O)=O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 17/20 0.72
MEN1 O00255 2/20 0.69
CYP1A2 P05177 2/20 0.69
CYP3A4 P08684 2/20 0.69
MAPT P10636 2/20 0.69
TSHR P16473 2/20 0.69
PTGS1 P23219 2/20 0.69
PTGS2 P35354 2/20 0.69
KMT2A Q03164 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
KDM4E B2RXH2 1/20 0.69
MLNR O43193 1/20 0.69
LMNA P02545 1/20 0.69
MMP1 P03956 1/20 0.69
MPO P05164 1/20 0.69
GLA P06280 1/20 0.69
ADORA3 P0DMS8 1/20 0.69
CYP2C9 P11712 1/20 0.69
HPGD P15428 1/20 0.69
TBXA2R P21731 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248880 0.88 LMNA (0.69) CYP19A1MEN1CYP1A2CYP3A4MAPT
SCHEMBL27183165 0.87 HTT (0.59) CYP19A1MEN1CYP1A2CYP3A4MAPT
SCHEMBL24193465 0.84 CYP19A1 (0.85) CYP19A1MEN1CYP1A2CYP3A4MAPT
SCHEMBL3293107 0.84 CYP19A1 (1.00) CYP19A1MEN1CYP1A2CYP3A4MAPT
Nimesulide SCHEMBL11790433 0.84 CYP19A1 (0.97) CYP19A1MEN1CYP1A2CYP3A4MAPT
SCHEMBL3296493 0.83 CYP19A1 (1.00) CYP19A1MEN1CYP1A2CYP3A4MAPT
SCHEMBL3237240 0.82 CYP19A1 (0.64) CYP19A1MEN1CYP1A2CYP3A4MAPT
SCHEMBL3301465 0.82 CYP19A1 (1.00) CYP19A1MEN1CYP1A2CYP3A4MAPT
Nimesulide SCHEMBL24882 0.82 CYP19A1 (1.00) CYP19A1MEN1CYP1A2CYP3A4MAPT
SCHEMBL8752473 0.82 HPGD (0.81) CYP19A1MEN1CYP1A2CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118773142-A Hybridoma cell strain secreting nimex Shu Lishan clone antibody and application thereof 江南大学 2024-10-15 CN disclosed
US-20160313639-A1 PHOTOSENSITIVE RESIN COMPOSITION, PIXEL LAYER, PROTECTIVE FILM, SPACER, THIN-FILM TRANSISTOR, COLOR FILTER, AND LIQUID CRYSTAL DISPLAY APPARATUS CHI MEI CORPORATION (TW) 2016-10-27 US disclosed
US-20150268554-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF CHI MEI CORPORATION (TW) 2015-09-24 US disclosed
US-9086532-B2 Blue photosensitive resin composition for color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-21 US disclosed
US-9081142-B2 Photosensitive resin composition for a color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-14 US disclosed
US-20150042931-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2015-02-12 US disclosed
US-20140346416-A1 PHOTOSENSITIVE RESIN COMPOSITION FOR A COLOR FILTER AND USES THEREOF CHI MEI CORPORATION (TW) 2014-11-27 US disclosed
US-20130222738-A1 COLOR LIQUID CRYSTAL DISPLAY DEVICE CHI MEI CORPORATION (TW) 2013-08-29 US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
EP-1984325-A2 SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2008-10-29 EP disclosed
US-20080045598-A1 Novel sulfonanilide analogs as selective aromatase modulators (SAMs) THE OHIO STATE UNIVERSITY (US) 2008-02-21 US disclosed
US-20080045598-A1 Novel sulfonanilide analogs as selective aromatase modulators (SAMs) THE OHIO STATE UNIVERSITY (US) 2008-02-21 US disclosed
WO-2007120379-A2 SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-10-25 WO disclosed
EP-1751097-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES Proteotech, Inc. (US) 2007-02-14 EP disclosed
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTAMED, INC. 2006-09-07 US disclosed
WO-2005113489-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH, INC. (US) 2005-12-01 WO disclosed
EP-0292911-A2 Process for the preparation of pure nitro-aminobenzene-compounds HOECHST AKTIENGESELLSCHAFT (DE) 1988-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 CYP19A1 4547/4885MEN1 2528/4885CYP1A2 1743/4885
US-20080045598-A1 Novel sulfonanilide analogs as selective aromatase modulators (SAMs) CYP19A1, AR, SULT2A1 CYP19A1 1/4885MEN1 3204/4885CYP1A2 23/4885
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies IAPP, SNCA, BACE2 CYP19A1 4442/4885MEN1 3425/4885CYP1A2 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.